Ypsomed is the leading developer and manufacturer of self-injection systems for liquid medications, offering the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices.

Our products and solutions

We offer a wide range of injection systems, digital health solutions,
and future-focused innovations for pharma clients.

Find the right injection solution

Explore our product finder to discover the best platform for your drug delivery needs.

Expert services and support

As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions.

Our platform ecosystem combines industrialized drug delivery technology with a set of built-in and optional services that support every stage of development.

Ypsomed enhances self-injection device platforms with integrated human factors services

Streamline clinical development with Ypsomed

Clear to Clinic

Clinic-ready devices to accelerate trial readiness and reduce study risk
Speed defines success in clinical development. Participant recruitment constraints, lengthy dose-finding protocols, and device bridging timelines create critical delays. Clear to Clinic enables the use of clinic-ready YpsoMate 1 mL and YpsoMate 2.25 mL autoinjectors in clinical trials to accelerate, simplify and derisk your program.

Explore Clear to Clinic

Latest insights

Ypsomed grows 20 % in core business and wins record number of customer projects

Ad hoc announcement pursuant to Art. 53 LR
Burgdorf, 20.05.2026, 07:00 a.m. – Ypsomed (SIX: YPSN) closed the financial year 2025/26 with consolidated revenue of CHF 731.0 million (prior year: CHF 748.9 million). Delivery Systems, the Company's core business segment, reported revenue of CHF …

Read more...

The development of drug-device combination products continues to evolve, with increasing attention on how clinical bridging between different delivery systems is handled. In this context, regulatory approaches that support more efficient and …

Read more...

Meet us in person

08
06

PFS & Injectable Drug Devices West Coast 2026

The Pre-Filled Syringes and Injectable Drug Devices West Coast Conference returns to San Diego in June, bringing pharma, biotech, and device experts together to advance combination product development.

09
06

Drug-Device Combination Products for Parenteral Use

A focused event on drug-device combination products at the Novartis Campus in Basel brings together experts across research, development and manufacturing, with Ypsomed's Jakob Lange contributing to a panel on high-volume injections.

15
06

HLTH Europe

HLTH Europe returns to Amsterdam, bringing together 5,000+ leaders from across the healthcare ecosystem to connect, exchange ideas, and engage with key decision-makers in one place.

Shape the future of selfcare with us

Ypsomed offers diverse career opportunities in an innovative, purpose-driven environment.

Our strategy Innovate. expand. engage.

Ypsomed pursues a sustainable corporate strategy

We pursue a long-term corporate strategy based on four pillars. These four pillars stand for areas of action in which we fulfill our responsibility to society as a sustainably oriented company.

Sustainability at Ypsomed

We are committed to acting responsibly towards our employees, our partners and society. We are also committed to the circular economy and reducing our carbon footprint.